Theralase Technologies Inc. announces that their latest research will be presented at the 2018 International Society for Optical Engineering Photonics West in San Francisco, California this upcoming January. Theralase, a leading biotech and Toronto-based company is focused on the commercialization of medical lasers to eliminate pain and the development of photodynamic compounds to destroy cancer.
SPIE Photonics West is the world’s largest photonics technologies event, consisting of three conferences and two world-class exhibitions. Every year over 20,000 participants attend to learn more about the latest research and technology in topics such as translational biophotonics, global healthcare, understanding the brain, new lasers for manufacturing, applications of 3D technologies, photonics-based consumer products, and other related subject matters.
There have been two oral presentations accepted by the following chairing committees: The Optical Methods for Tumor Treatment and Detection Mechanisms and Techniques in Photodynamic Therapy XXVII and Therapeutics and Diagnostics in Urology. The topics discuss targeting non-small cell lung cancer by photodynamic therapy and monitoring irradiance during full bladder irradiation.
“The company has previously reported that in the phase Ib clinical study of non-muscle invasive bladder cancer that the first 3 patients treated at the maximum recommended starting dose were visibly free of tumours at 3 months post-treatment,” said Arkady Mandel, MD, PhD, DSc, chief scientific officer of Theralase. “Theralase will now present to the scientific and medical community, the results that have shown the ability TLD-1433-based PDT to destroy non-small cell lung cancer in various clinical models. This latest peer-reviewed research supports the company’s clinical mandate to advance the PDT technology platform across multiple oncological targets.”
The bio-stimulative capabilities of Theralase laser systems include healing neural muscular skeletal conditions through pain elimination, inflammation reduction, and increased tissue regeneration. Their lasers penetrate deeper below the skin surface and heal tissue faster than other cold lasers on the market.
“This latest peer-reviewed research confirms that the company is on the right track to provide support for the design and commencement of additional phase Ib clinical studies, utilizing the company’s cutting-edge technology for patients inflicted with various forms of this deadly disease,” stated Roger Dumoulin-White, president and CEO of Theralase.
Scanning for skin cancer with the sKan Next Post:
Cancer research presented at the Canadian Cancer Research Conference